The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

NCT04161014 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Pneumoconiosis Coal
Asbestosis
Silicosis

Interventions

DRUG: Nintedanib 150 MG [Ofev]

Sponsor

Holdsworth House Medical Practice

Collaborators

[object Object]